Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDI in pharma: Supply...

    FDI in pharma: Supply of NLEM drugs to be maintained for 5 years

    Written by savita thakur thakur Published On 2016-06-26T16:06:37+05:30  |  Updated On 26 Jun 2016 4:06 PM IST
    FDI in pharma: Supply of NLEM drugs to be maintained for 5 years

    New Delhi : Foreign pharma firms wanting to invest up to 74 per cent in domestic companies will have to commit to maintain the same production level and supply of essential drugs at the time of investment for a period of five years, according to the latest relaxed norms of FDI.


    Further, R&D expenses will also have to be maintained in value terms for five years at an absolute quantitative level at the induction of the FDI of up to 74 per cent, which has now been allowed under the automatic route.


    In a press note, DIPP said: "The production level of National List of Essential Medicines (NLEM) drugs and/or consumables and their supply to the domestic market at the time of induction of FDI, being maintained over the next five years at an absolute quantitative level."


    The benchmark for this level would be decided with reference to the level of production of NLEM drugs and or consumables in the three financial years immediately preceding the year of induction of FDI, it said.


    Of these, the highest level of production in any of these three years would be taken as the level, it added.


    Besides, R&D expenses need to be being maintained in value terms for five years at an absolute quantitative level at the induction of FDI.


    "The benchmark for this level would be decided with reference to the highest level of R&D expenses which has been incurred in any of the three financial years immediately preceding the year of induction of FDI," DIPP said.


    Moreover, the administrative ministry will be provided complete information pertaining to the transfer of technology, if any, along with induction of foreign investment into the investee company, it added.


    DIPP said the above mentioned conditions will not be applicable to greenfield as well as brownfield projects of medical device industry.


    The government has allowed up to 74 per cent foreign direct investment in the existing pharmaceutical companies through automatic route, with an aim to promote the sector.


    Earlier, 100 per cent FDI was permitted through government approval route.

    automatic routeDIPPFDIforeign direct investmentInvestmentNational List of Essential MedicinesNLEMNLEM drugsPharma sector in india
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok